A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS

Neurology

Volumn 59, Issue 10, 2002, Pages 1507-1517

  Clanet, M ^a   Radue, E W ^b   Kappos, L ^b   Hartung, H P ^c   Hohlfeld, R ^d   Sandberg Wollheim, M ^e   Kooijmans Coutinho, M F ^f   Tsao, E C ^f   Sandrock, A W ^f   Kristoferitsch, W ^g   Schrieber, ^g   Schlederer, ^g   Seeldrayers, P ^g   Piette, ^g   Papacostas, S ^g   Kyriallis, K ^g   Pantzaris, ^g   Brochet, B ^g   Gayou, A ^g   Rouanet, M ^g   Rouant, F ^g   Confavreux, C ^g   Riche, G ^g   Blanc, S ^g   Achiti, J ^g   Magnier, C ^g   Aubertin, P ^g   Mekies, C ^g   Brassat, D ^g   Thalamas, C ^g   Vuilleman, C ^g   Senard, A ^g   Lau, G ^g   Cesaro, P ^g   Degos, F ^g   Defer, G ^g   Schaeffer, S ^g   Edan, G ^g   De Marco, ^g   Cahagne, V ^g   Belliard, S ^g   Lyon Caen, O ^g   Stankoff, B ^g   Lubetzki, C ^g   Arnulf, I ^g   Damier, P ^g   Pelletier, J ^g   Tamman, D ^g   Suchet, L ^g   Dalecky, A ^g   Rumbach, L ^g   Moulin, ^g   Berger, E ^g   Roullet, E ^g   Pez, D ^g   Heinzlef, O ^g   Lecanuet, P ^g   Vermersch, P ^g   Engles, A ^g   Dengler, R ^g   Heidenreich, F ^g   Lindert, ^g   Koehler, ^g   Windhagen, ^g   Steiner, ^g   Zschenderlein, R ^g   Luenemann, J ^g   Gelderblom, H ^g   Kassim, N ^g   Storch Hagenlocher, B ^g   Koerner, ^g   Vogt Schaden, ^g   Stingle, ^g   Storch Hagenlocher, ^g   Sailer, M ^g   Matzke, ^g   Dose, ^g   Weiler, C ^g   Kunze, K ^g   Heesen, C ^g   Bamborschke, P ^g   Petereit, H ^g   Liu, ^g   Nolden, ^g   Grunwald, F ^g   Menck, ^g   Grupe, ^g   Rieckmann, P ^g   Weilbach, ^g   Flachenecker, ^g   Chan, ^g   Maurer, ^g   De Keyser, J ^g   Zwanniken, G ^g   Azurdrager, ^g   Montalban, X ^g   Nos, ^g   Fernandez O ^g   Tamayo J A , ^g   more..

^a CHU PURPAN   (France)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Neurological Clinic   (Germany)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f BIOGEN   (United States)

^g University Hospitals ^*

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY; PARACETAMOL; PREDNISOLONE; PREDNISONE; STEROID;

ACCIDENT; ADULT; BRAIN INJURY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISABILITY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EUROPE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; IMAGE ANALYSIS; IMMUNOGENICITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; TREATMENT OUTCOME;

EID: 0037180468     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000032256.35561.D6     Document Type: Review

References (23)

1. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
2. Rudick RA, Fisher E, Lee J-C, Simon J, Jacobs L, and the Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999;53:1698-1704.
3. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol 2000;48:885-892.
4. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
6. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-1504.
7. The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon β-1a dose response in relapsing-remitting MS. Neurology 1999;53:679-686.
8. Clanet M. Interferon beta for the treatment of multiple sclerosis: Do clinical data support the existence of a ceiling effect? Clin Drug Invest 2001;21:307-318.
9. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-1636.
10. Jacobs L, Munschauer FE. Treatment of multiple sclerosis with interferons. In: Rudick RA, Goodkin DE, eds. Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives. London: Springer, 1992:223-250.
11. European Study Group on Interferon-Beta-1a in MS. Double-blind, randomized, multicenter, dose-comparison study of interferon beta-1a (AVONEX): Rationale, design and baseline data. Mult Scler 2001;7:179-183.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
13. Rudick R, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272.
14. Confavreux C, Vukusic S, Moreau T, Adeline P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
15. Grimaud J, Lai M, Thorpe J, et al. Quantification of MRI lesion load in multiple sclerosis: A comparison of three computer-assisted techniques. Magn Reson Imaging 1996;14: 495-505.
16. Molyneux PD, Tofts PS, Fletcher A, et al. Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: A comparison of two computer assisted techniques. J Neurol Neurosurg Psychiatry 1998;65:42-47.
17. Taves DR. Minimization: A new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974; 15:443-453
18. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978;37: 849-857.
19. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34: 585-612.
20. Freitag P, De Battista E, Hardmeier M, Koojmans M, Kappos L, Radü EW. Counting new and enlarging T2 lesions: What is the best interval? Mult Scler 2001;7(suppl 1):S88. Abstract.
21. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
22. The European Agency for the Evaluation of Medicinal Products. Rebif. In: European Public Assessment Reports (EPAR) 2001 [online]. Available at: http://www.eudra.org/humandocs/ humans/EPAR/htm. Accessed June 6, 2001.
23. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.